Biologics in Spondyloarthropathy

Speciality: Rheumatology

Description:

A warm welcome to all the medical professionals in this interesting session on Biologics in Spondyloarthropathy
Biologics have transformed the treatment landscape for spondyloarthropathies, a group of inflammatory rheumatic diseases that includes ankylosing spondylitis, psoriatic arthritis, and other related conditions. These targeted therapies specifically inhibit key molecules involved in the inflammatory process, such as tumor necrosis factor (TNF), interleukin-17 (IL-17), and interleukin-12/23 (IL-12/23), providing effective control of symptoms and halting disease progression. The introduction of biologics has offered significant relief for patients who do not respond adequately to conventional treatments like nonsteroidal anti-inflammatory drugs (NSAIDs) and disease-modifying antirheumatic drugs (DMARDs).
TNF inhibitors, including etanercept, infliximab, and adalimumab, were among the first biologics approved for spondyloarthropathies and have shown remarkable efficacy in reducing inflammation, improving physical function, and enhancing quality of life. More recently, IL-17 inhibitors like secukinumab and ixekizumab have been approved, offering new options for patients, especially those who do not respond to or tolerate TNF inhibitors. These biologics have demonstrated substantial improvements in spinal and joint symptoms, as well as skin manifestations in conditions like psoriatic arthritis.
Therefore, get an overall knowledge of biologics in spondyloarthropathy
 

See More Webinars @ Hidoc Webinars